Metraipolis › archive › dc_609fe3dfb965
Focus on Semaglutide 2.4 mg/week for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis — Europe PMC PMID:41144918
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41144918
- DOI
- 10.1111/liv.70407
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-08T21:18:59.167Z
- SHA-256 of the archived text
9f65cdb9cb1e01b32a65b37341de4bc9f6607cff56c1e6b77711ac847cfd6052- Stable URL of this page
https://metraipolis.com/documento/dc_609fe3dfb965
How to cite
Focus on Semaglutide 2.4 mg/week for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis — Europe PMC PMID:41144918 — Europe PMC (en), https://europepmc.org/article/MED/41144918 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_609fe3dfb965 (Metraipolis archive dc_609fe3dfb965, sha256 9f65cdb9cb1e01b32a65b37341de4bc9f6607cff56c1e6b77711ac847cfd6052)
BibTeX
@misc{dc609fe3dfb965,
title = {Focus on Semaglutide 2.4 mg/week for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis — Europe PMC PMID:41144918},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41144918},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_609fe3dfb965; sha256 9f65cdb9cb1e01b32a65b37341de4bc9f6607cff56c1e6b77711ac847cfd6052},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41144918. Agents can read the archived copy with the MCP tool read_document.